Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls.

Tytuł:: Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls.
Autorzy:: Jiménez-Fernández S; CTS-549 Research Group, Institute of Neurosciences, University of Granada, Granada, Spain.; Child and Adolescent Mental Health Unit, Jaén Medical Center, Jaén, Spain.
Gurpegui M; CTS-549 Research Group, Institute of Neurosciences, University of Granada, Granada, Spain.; Department of Psychiatry, University of Granada, Granada, Spain.
Garrote-Rojas D; Department of Pedagogy, University of Granada, Granada, Spain.
Gutiérrez-Rojas L; CTS-549 Research Group, Institute of Neurosciences, University of Granada, Granada, Spain.; Department of Psychiatry, University of Granada, Granada, Spain.; Psychiatry Service, San Cecilio University Hospital, Granada, Spain.
Carretero MD; Department of Psychiatry, University of Granada, Granada, Spain.
Correll CU; Department of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
Źródło:: Bipolar disorders [Bipolar Disord] 2021 Mar; Vol. 23 (2), pp. 117-129. Date of Electronic Publication: 2020 Sep 10.
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Publication: Copenhagen : Wiley-Blackwell Munksgaard
Original Publication: Copenhagen, Denmark : Munksgaard, 1999-
MeSH Terms:: Antioxidants*
Bipolar Disorder*/drug therapy
Glutathione Peroxidase/metabolism ; Humans ; Oxidative Stress ; Superoxide Dismutase/metabolism ; Thiobarbituric Acid Reactive Substances
References:: Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS One. 2013;10:e1001547.
Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148:161-169.
Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575-1586.
Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386:2145-2191.
Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64:543-552.
Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68:241-251.
Ferrari AJ, Stockings E, Holly JK, et al. The prevalence and burden of bipolar disorder : findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18:440-450.
Garcia-Portilla MP, Saiz PA, Bascaran MT, et al. Cardiovascular risk in patients with bipolar disorder. J Affect Disord. 2009;115:302-308.
De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15-22.
McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep. 2009;9:51-59.
Malhotra N, Kulhara P, Chakrabarti S, Grover S. A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord. 2013;150:653-658.
Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163-180.
Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7:e1007.
Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29:141-152.
Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34:301-309.
Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17:175-179.
Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;2012(141):1-10.
Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. J Biochemy Cell Biol. 2007;39:44-84.
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858-6862.
Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. New York: Oxford University Press; 2015.
Girotti AW. Lypid hydroperoxide generation, turnover and effector action in biological systems. J Lipid Res. 1998;39:1529-1542.
Sakano N, Takahashi N, Wang DH, et al. Plasma 3-nitrotyrosine, urinary 8-isoprostane and 8-OHdG among healthy Japanese people. Free Radic Res. 2009;43:183-192.
Anderson G, Maes M. Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr Psychiatry Rep. 2015;17:8.
Bosetti F, Rintala J, Seemann R, et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry. 2002;7:845-850.
Himmerich H, Bartsch S, Hamer H, et al. Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-CD40-stimulated blood in vitro. Oxid Med Cell Longev. 2014;806162.
Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27-53.
Fornito A, Malhi GS, Lagopoulos J, et al. In vivo evidence for early neurodevelopmental anomaly of the anterior cingulate cortex in bipolar disorder. Acta Psychiatr Scand. 2007;116:467-472.
Mechawar N, Savitz J. Neuropathology of mood disorders: do we see the stigmata of inflammation? Transl Psychiatry. 2016;6:1-16.
Buoli M, Caldiroli A, Caletti E, Zugno E, Altamura AC. The impact of mood episodes and duration of illness on cognition in bipolar disorder. Compr Psychiatry. 2014;55:1561-1566.
López-Jaramillo C, Lopera-Vásquez J, Gallo A, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12:557-567.
Berk M, Post R, Ratheesh A, et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry. 2017;16:236-244.
De Sousa RT, Zarate CA, Zanetti MV, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res. 2014;50:36-41.
Cudney LE, Sassi RB, Behr GA, et al. Alterations in circadian rhythms are associated with increased lipid peroxidation in females with bipolar disorder. Int J Neuropsychopharmacol. 2014;17:715-722.
Mansur RB, Rizzo LB, Santos CM, et al. Bipolar disorder course, impaired glucose metabolism and antioxidant enzymes activities: a preliminary report. J Psychiatr Res. 2016;80:38-44.
Andreazza AC, Kauer-Sant'Anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111:135-144.
Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218:61-68.
Rowland T, Perry BI, Upthegrove R, et al. Stress mediators and mood state in bipolar disorder: systematic review and meta-analyses. Br J Psychiatry. 2018;213:514-525.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8:336-341.
Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-1457.
Tsai MC, Huang TL. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord. 2015;173:22-26.
Machado-Vieira R, Andreazza AC, Viale CI. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett. 2007;421:33-36.
Bartoli F, Crocamo C, Mazza MG, Clerici M, Carrà G. Uric acid levels in subjects with bipolar disorder: a comparative meta-analysis. J Psychiatr Res. 2016;81:133-139.
Singh N, Mcmahon H, Bilderbeck A, et al. Plasma glutathione suggests oxidative stress is equally present in early- and late- onset bipolar disorder. Bipolar Disord. 2019;21:61-67.
Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008;107:89-94.
Ozcan ME, Gulec M, Ozerol E, Polat R. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004;19:89-95.
Kapczinski F, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32:675-692.
Seet RCS, Lee CYJ, Loke WM, et al. Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress? Free Radic Biol Med. 2011;50:1787-1793.
Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev. 2012;70:257-265.
Tumova E, Sun W, Jones PH, et al. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013;2013:1-10.
Bengesser SA, Lackner N, Birner A, et al. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder - gender and obesity effects. J Affect Disord. 2015;172:367-374.
Jornada LK, Valvassori SS, Steckert AV, et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res. 2011;2011(45):162-168.
Akarsu S, Bolu A, Aydemir E, Zincir SB. The relationship between the number of manic episodes and oxidative stress indicators in bipolar disorder. Korean Neuropsychiatr Assoc. 2018;15:514-519.
Selek S, Altindag A, Saracoglu G, Aksoy N. Oxidative markers of myeloperoxidase and catalase and their diagnostic performance in bipolar disorder. J Affect Disord. 2015;181:92-95.
Jiménez-Fernández S, Gurpegui M, Díaz-Atienza F, Pérez-Costillas L, Gerstenberg M, Correll CU. Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. J Clin Psychiatry. 2015;76:1658-1667.
Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400-409.
Steenkamp LR, Hough CM, Reus VI, et al. Severity of anxiety- but not depression- is associated with oxidative stress in Major Depressive Disorder. J Affect Disord. 2017;219:193-200.
Bartoli F, Crocamo C, Carrà G. Differences in serum uric acid between ‘unipolar’ and ‘bipolar’ depression. Bipolar Disord. 2019;21:280-281.
Thomas SP, Nandhra HS, Singh SP. Pharmacologic treatment of first-episode schizophrenia: a review of the literature. Prim Care Companion J Clin Psychiatry. 2012;14:pii:PCC.11r01198.
Haddad JJ. Glutathione depletion is associated with augmenting a proinflammatory signal: evidence for an antioxidant/pro-oxidant mechanism regulating cytokines in the alveolar epithelium. Cytokines Cell Mol Ther. 2000;6:177-187.
Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:676-692.
Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012;36:764-785.
Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem. 2006;97:1634-1658.
Bazan NG, Marcheselli VL, Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann N Y Acad Sci. 2005;1053:137-147.
Gigante AD, Young LT, Yatham LN, et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol. 2001;14:1075-1089.
Fullerton JM, Tiwari Y, Agahi G, et al. Assessing oxidative pathway genes as risk factors for bipolar disorder. Bipolar Disord. 2010;12:550-556.
Galecki P, Maes M, Florkowski A, et al. An inducible nitric oxide synthase polymorphism is associated with the risk of recurrent depressive disorder. Neuroscie Lett. 2010;486:184-187.
Bortolasci CC, Vargas HO, Souza-Nogueira A, et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord. 2014;159:23-30.
Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:135-145.
Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2017;13:75-83.
Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81-86.
Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011;135:389-394.
Contributed Indexing:: Keywords: antioxidants; bipolar disorder; meta-analysis; oxidative stress; polarity
Substance Nomenclature:: 0 (Antioxidants)
0 (Thiobarbituric Acid Reactive Substances)
EC 1.11.1.9 (Glutathione Peroxidase)
EC 1.15.1.1 (Superoxide Dismutase)
Entry Date(s):: Date Created: 20200812 Date Completed: 20210426 Latest Revision: 20220531
Update Code:: 20240105
DOI:: 10.1111/bdi.12980
PMID:: 32780547
: Czasopismo naukowe

Pełny tekst

Objective: To investigate oxidative stress markers and antioxidants in bipolar disorder (BD).
Methods: Electronic MEDLINE/PubMed/Cochrane-Library/Scopus/TripDatabase search until 06/30/2019 for studies comparing antioxidant or oxidative stress markers between BD and healthy controls (HCs). Standardized mean differences (SMD) and 95% confidence intervals (CIs) were calculated for ≥3 studies.
Results: Forty-four studies (n = 3,767: BD = 1,979; HCs = 1,788) reported on oxidative stress markers malondialdehyde (MDA), thiobarbituric acid reactive substances (TBARS), and total nitrites; antioxidants glutathione (GSH), uric acid, and zinc; or antioxidantenhancing enzymes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), and GSH-transferase (GST). Compared with HCs, BD was associated with higher GST (P = .01), CAT (P = .02), nitrites (P < .0001), TBARS (P < .0001), MDA (P = .01), uric acid (P < .0001), and lower GSH (P = .006), without differences in SOD, GPX, and zinc. Compared to HCs, levels were higher in BD-mania for TBARS (P < .0001) and uric acid (P < .0001); in BD-depression for TBARS (P = .02); and BD-euthymia for uric acid (P = .03). Uric acid levels were higher in BD-mania vs BD-depression (P = .002), but not vs BD euthymia. TBARS did not differ between BD-mania and BD-depression. Medication-free BD-mania patients had higher SOD (P = .02) and lower GPX (P < .0001) than HCs. After treatment, BD did not differ from HCs regarding SOD and GPX.
Conclusions: Beyond a single biomarker of oxidative stress, the combination of several parameters appears to be more informative for BD in general and taking into account illness polarity. BD is associated with an imbalance in oxidative stress with some phase-specificity for uric acid and TBARS and possible treatment benefits for SOD and GPX. Future studies should take into account confounding factors that can modify oxidative stress status and simultaneously measure oxidative stress markers and antioxidants including different blood sources.
(© 2020 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja